06 March 2017

Result of General Meeting and Open Offer

This announcement contains inside information

Collagen Solutions completes fundraising of up to £10.8 million to fuel growth

On 14 February 2017, Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, announced a conditional Placing (the "Placing") and Open Offer ("Open Offer") with new and existing investors. In addition, the Company announced that it had received a conditional commitment from Norgine Ventures to subscribe up to £4.0 million in secured private bonds with Warrants. The resolutions relating to (amongst other things) the Placing and Offer were duly passed at the General Meeting of the Company held earlier today.

The Open Offer, which closed at 11:00am on 2 March 2017, raised a total of approximately £0.64 million through the issue at Admission of 12,877,788 New Ordinary Shares. Accordingly, the aggregate amount raised pursuant to the Placing and Open Offer is approximately £6.83 million (before expenses).

In conjunction with the Placing and Open Offer, an application has been made for 136,677,787 new Ordinary Shares to be admitted to trading on AIM ("Admission"). It is expected that Admission will become effective at 8:00am on 7 March 2017. Following Admission, the Company will have 316,299,077 Ordinary Shares in issue admitted to trading on AIM.

Further details of the Placing and Open Offer were set out in the Circular published by the Company on 14 February 2017.

Unless otherwise defined, capitalised terms shall have the same meaning as defined in the circular posted to Shareholders on 14 February 2017, which is available to view on the Company's website at www.collagensolutions.com

About Collagen Solutions:

Collagen Solutions Plc is a global provider of medical grade collagen formulations and components for use in regenerative medicine, medical devices and in-vitro diagnostics and research. The capabilities of the Company include the provision of native, soluble and powdered collagen formulations, processed and semi-processed tissues such as pericardium, bone, and blood vessels, and expertise in the development and contract manufacture of collagen components for use as engineered tissue scaffolds and other medical devices. These products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology. Collagen Solutions' unique offering extends beyond material supply and contract services through the highly skilled staff who support customers through the various stages of development and regulatory approval. For additional information, please visit www.collagensolutions.com.

 

Collagen Solutions Plc Contact via Walbrook
Jamal Rushdy, Chief Executive Officer 
Gill Black, Chief Financial Officer  
   
Cenkos Securities plc (Nominated Adviser & Broker) Tel: 0207 397 8900
Stephen Keys  
Steve Cox  
Callum Davidson  
   
Walbrook PR Tel: 020 7933 8780 or collagen@walbrookpr.com
Mike Wort Mob: 07900 608 002
Anna Dunphy Mob: 07876 741 001